This page is intended for healthcare professionals.
Information for your patients with Diabetes.
Novo Nordisk
At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
This page provides access to a range of support materials that you can utilise to support your patients living with diabetes. If you would like to contact Novo Nordisk, please visit www.novonordisk.co.uk/contact-us.
Educational Information for Patients with Diabetes
A range of patient educational material are available in both printed and electronic formats. The materials are designed to provide information for patients to support the management of diabetes. They are intended to provide educational support and supplement your clinical advice.
Patients ‘Getting Started’ Leaflets
If you have made a decision to start a patient on a Novo Nordisk diabetes medicine, there are a range of materials including ‘Guidance for patients leaflets’ for our medicines, which are intended to support patients getting started on their treatment and to supplement your clinical advice. They are not intended to affect your prescribing decisions.
Links to Prescribing Information for each medicine are available on www.emcpi.com and the links are below for reference (new window will open).
Actrapid® (Insulin human, rDNA)
For Prescribing Information please click here
Fiasp®▼ (Fast-acting insulin aspart)
For Prescribing Information please click here
Glucagen® (Glucagon)
For Prescribing Information please click here
Insulatard® (Insulin human, rDNA)
For Prescribing Information please click here
Levemir® (Insulin detemir)
For Prescribing Information please click here
NovoMix® 30 (Biphasic insulin aspart)
For Prescribing Information please click here
NovoRapid® (Insulin aspart)
For Prescribing Information please click here
Ozempic®▼(Semaglutide)
For Prescribing Information please click here
Rybelsus®▼(Semaglutide tablets)
For Prescribing Information please click here
Tresiba® (Insulin degludec)
For Prescribing Information please click here
Victoza® (Liraglutide)
For Prescribing Information please click here
Xultophy® (Insulin degludec/liraglutide)
For Prescribing Information please click here
(Please note: the links for prescribing information and adverse event reporting will open the page in a new browser window).
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.
Information and resources listed on this page are provided free of charge by Novo Nordisk Limited. If you would like to contact a member of the Novo Nordisk team, please use the contact details on www.novonordisk.co.uk/contact-us.
UK20DI00425 Date of preparation: January 2021